Venus Concept Inc. (NASDAQ:VERO) Sees Significant Increase in Short Interest

Venus Concept Inc. (NASDAQ:VERO) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 199,499 shares, a growth of 113.1% from the December 15th total of 93,597 shares. Currently, 19.5% of the shares of the company are short sold. Based on an average daily volume of 4,414,860 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 4,414,860 shares, the short-interest ratio is presently 0.0 days. Currently, 19.5% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Venus Concept in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Venus Concept Stock Down 5.3%

VERO stock opened at $1.44 on Wednesday. Venus Concept has a 52 week low of $1.39 and a 52 week high of $14.50. The business has a 50-day simple moving average of $1.79 and a 200 day simple moving average of $2.19. The company has a quick ratio of 0.59, a current ratio of 0.90 and a debt-to-equity ratio of 1.59. The company has a market cap of $2.04 million, a PE ratio of -0.03 and a beta of -0.04.

Venus Concept (NASDAQ:VERO) last released its earnings results on Thursday, November 13th. The company reported ($12.14) EPS for the quarter, missing the consensus estimate of ($3.61) by ($8.53). The firm had revenue of $13.78 million during the quarter, compared to the consensus estimate of $14.48 million. Venus Concept had a negative net margin of 92.76% and a negative return on equity of 1,904.25%.

Venus Concept Company Profile

Venus Concept Ltd. (NASDAQ: VERO) is a Canada-based medical aesthetic device company that designs, develops and commercializes minimally and noninvasive solutions for face and body rejuvenation. The company’s core product portfolio leverages proprietary technologies such as multi-polar radio frequency, pulsed electromagnetic fields and intense pulsed light to offer treatments for skin tightening, body contouring, wrinkle reduction and vascular lesion removal.

Among its flagship offerings are the Venus Legacy platform, which combines radio frequency and electromagnetic pulses for cellulite reduction and circumferential reduction, and the Venus Versa system, a multi-application device for facial revitalization, acne treatment, hair removal and photorejuvenation.